Tradition Capital Management LLC Reduces Stake in Eli Lilly and Co (LLY)

Tradition Capital Management LLC trimmed its stake in shares of Eli Lilly and Co (NYSE:LLY) by 10.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 10,785 shares of the company’s stock after selling 1,223 shares during the period. Tradition Capital Management LLC’s holdings in Eli Lilly and were worth $910,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Beach Investment Management LLC. bought a new position in Eli Lilly and in the 2nd quarter worth approximately $400,000. Alps Advisors Inc. grew its holdings in Eli Lilly and by 3.4% in the 2nd quarter. Alps Advisors Inc. now owns 578,098 shares of the company’s stock worth $47,577,000 after buying an additional 19,110 shares in the last quarter. Legal & General Group Plc grew its holdings in Eli Lilly and by 2.8% in the 2nd quarter. Legal & General Group Plc now owns 5,101,196 shares of the company’s stock worth $419,840,000 after buying an additional 136,660 shares in the last quarter. BARING ASSET MANAGEMENT Ltd bought a new position in Eli Lilly and in the 2nd quarter worth approximately $1,668,000. Finally, Highstreet Asset Management Inc. bought a new position in Eli Lilly and in the 2nd quarter worth approximately $814,000. Institutional investors and hedge funds own 76.45% of the company’s stock.

A number of equities analysts recently issued reports on the company. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, December 5th. Credit Suisse Group reissued a “hold” rating and issued a $80.00 price objective on shares of Eli Lilly and in a report on Friday, February 2nd. Leerink Swann increased their price objective on Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and increased their price objective for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Finally, Jefferies Group set a $100.00 price objective on Eli Lilly and and gave the stock a “buy” rating in a report on Tuesday, January 16th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $92.02.

Eli Lilly and Co (NYSE:LLY) opened at $74.21 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The stock has a market capitalization of $84,476.02, a price-to-earnings ratio of -371.03, a price-to-earnings-growth ratio of 1.41 and a beta of 0.23. Eli Lilly and Co has a one year low of $74.19 and a one year high of $89.09.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The firm had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the company posted $0.95 EPS. equities research analysts predict that Eli Lilly and Co will post 4.87 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently -1,039.95%.

In other Eli Lilly and news, SVP Susan Mahony sold 36,585 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the transaction, the senior vice president now directly owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 259,610 shares of company stock valued at $22,727,406. 0.20% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Tradition Capital Management LLC Reduces Stake in Eli Lilly and Co (LLY)” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.com-unik.info/2018/02/09/tradition-capital-management-llc-reduces-stake-in-eli-lilly-and-co-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit